Desk›Healthcare› Cohance Lifesciences Ltd
Cohance Lifesciences Ltd
BSE 543064 · NSE COHANCE · ISIN INE03QK01018 · Group A · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹450.65
-0.73%
BSE close, 28 August 2026
₹17,241.75 cr
38.3 cr shares · Small cap
₹7,312.19 cr
as published
97.1× · 7.81×
EPS ₹4.64 · BV ₹57.70
2,030.50 / 228.71
₹ cr, as filed
27
5 selected · 19%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -56.6% |
|---|---|
| Against 52-week low | +68.2% |
| Day change | -0.73% |
| Size band | Small cap |
| Index membership | NIFTY 500 |
Valuation as published by BSE
| Earnings per share | ₹4.64 |
|---|---|
| Price / earnings | 97.12× |
| Price / book | 7.81× |
| Book value — derived, price ÷ P/B | ₹57.70 |
| Return on equity | 8.05% |
| Operating margin | 10.74% |
| Net margin | 0.39% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 8.04%
- ROE as published
- 8.05%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 359.89 | 1.41 | 0.04 | 10.74% | 0.39% |
| Mar-26 · Q | 567.55 | 34.56 | 0.90 | 17.49% | 6.09% |
| FY25-26 | 2,030.50 | 228.71 | 5.98 | 23.13% | 11.26% |
Quarter on quarter
- Revenue, quarter on quarter
- -36.6%
- Net profit, quarter on quarter
- -95.9%
- Operating margin, quarter on quarter
- -675 bps
Disclosure profile 27 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Board Outcome | 1 |
| Change in Management | 1 |
| Credit Rating | 1 |
| Press Release | 1 |
| Results | 1 |
| Selected sub-total | 5 |
| Procedural | |
| Analyst / Investor Meet | 5 |
| General | 5 |
| AGM / EGM | 3 |
| Newspaper Publication | 2 |
| Annual Report | 1 |
| BRSR | 1 |
| Board Meeting | 1 |
| Compliance Certificate | 1 |
| Outcome | 1 |
| SAST | 1 |
| Trading Window | 1 |
| Procedural sub-total | 22 |
| Total | 27 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
27 filings · 5 selected · busiest 2026-08-05
Filing rhythm · the twelve most recent
2026-08-272026-10-09
SelectedProcedural
Filings
27 in the window · 12 earlier on record
-
9 October 2026 ·
Change in Management
Appointment of Mr. Abhimanyu Ojha as Chief Financial Officer of the Company
Company Update / Change in Management View filing →
-
7 October 2026 ·
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under 74(5) of SEBI (DP) Regulations 2018
Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
-
6 October 2026 ·
ESG Rating By Crisil ESG Ratings & Analytics Limited
ESG Rating by Crisil ESG ratings & Analytics Limited
Company Update / General View filing →
-
28 September 2026 ·
Closure of Trading Window
Closure of Trading Window
Insider Trading / SAST / Closure of Trading Window View filing →
-
21 September 2026 ·
-
18 September 2026 ·
-
17 September 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
Scrutinizer`s report
AGM/EGM / AGM View filing →
-
17 September 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of Annual General Meeting
AGM/EGM / AGM View filing →
-
17 September 2026 ·
Analyst / Investor Meet - Intimation
Investor Meet
Company Update / Analyst / Investor Meet View filing →
-
3 September 2026 ·
Press Release / Media Release
Press Release
Company Update / Press Release / Media Release View filing →
-
3 September 2026 ·
Board Meeting Outcome for Outcome Of The Committee Meeting
Outcome of Committee Meeting
Others / Outcome without intimation View filing →
-
27 August 2026 ·
Analyst / Investor Meet - Intimation
Investors Meet
Company Update / Analyst / Investor Meet View filing →
-
27 August 2026 ·
-
26 August 2026 ·
Business Responsibility and Sustainability Reporting (BRSR)
BRSR
Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →
-
26 August 2026 ·
-
26 August 2026 ·
-
13 August 2026 ·
-
12 August 2026 ·
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for DSP Trustee Pvt Ltd
Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 View filing →
-
11 August 2026 ·
Analyst / Investor Meet - Outcome
Earnings Call Transcript
Company Update / Analyst / Investor Meet View filing →
-
6 August 2026 ·
-
5 August 2026 ·
Analyst / Investor Meet - Outcome
Con Call audio link
Company Update / Analyst / Investor Meet View filing →
-
5 August 2026 ·
Completion Of USFDA Inspection
Completion of USFDA Inspection
Company Update / General View filing →
-
5 August 2026 ·
-
5 August 2026 ·
Board Meeting Outcome for Outcome Of The Board Meeting
Outcome of the Board Meeting
Board Meeting / Outcome of Board Meeting View filing →
-
23 July 2026 ·
Allotment Of Equity Shares Pursuant To Exercise Of Stock Options And Grant Of Stock Options To Certain Eligible Employees Of The Company
Allotment of Equity Shares pursuant to exercise of Stock Options and grant of Stock Options to certain eligible employees of the Company
Company Update / General View filing →
-
23 July 2026 ·
Analyst / Investor Meet - Intimation
Results Conference Call
Company Update / Analyst / Investor Meet View filing →
-
23 July 2026 ·
Board Meeting Intimation for Considering The Unaudited Financial Results (Standalone And Consolidated) Of The Company, For The Quarter Ended 30 June 2026
Cohance Lifesciences Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve the Unaudited Financial ....
Board Meeting / Board Meeting View filing →
RSS feed for Cohance Lifesciences Ltd · the 50 most recent filings